Radiopharmaceutical dose distribution in different organs and tissues for Lu-177 with different carrier

Abstract

177Lu refers to rare earth elements from a group of lanthanides. Relative to its short time span, 177Lu has virtually pervaded all areas of in vivo radionuclide therapy and becomes one of important keys for therapeutic radionuclides of choice for targeted radionuclide therapy. The rising interest in the use of 177Lu in targeted molecular therapies has primarily developed from recent unmatched advances in molecular and cell biology, which include the use of peptides targeted to cell surface receptors, which are overexpressed on the surface of tumour cells. Therefore, the use of 177Lu-labelled radiopharmaceuticals have been the major factors evoking excitement among researchers and capturing the imagination of the clinical community thanks to advances in molecular and cellular biology. In this work, radiopharmaceutical comparison for 177Lu absorbed dose in health human organs and tissues is presented. The comparison between unlabelled 177Lu (ionic form) and labelled with 177Lu-MDP (methylenediphosphonate) a...